COLUMBUS, Ohio, & FORT WORTH, Texas–(BUSINESS WIRE)–The Center for Cancer and Blood Disorders (The CenterTX) and Deep Lens today announced that they will partner to deploy artificial intelligence (AI)-based clinical trial screening and enrollment solution, VIPER(TM), into the Texas-based network. VIPER uses proprietary, cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process. The CenterTX serves thousands of patients across 10 locations in North Texas. This partnership will broaden its clinical trial offering by improving efficiencies related to recruitment and by expanding the number of available trials for eligible patients.
“We are a forward-looking practice that takes pride in our ability to offer our patient community a robust suite of services and cutting-edge treatment options designed to meet their individual needs. This includes access to new technologies and innovative therapies through participation in clinical trials,” said Barry Russo, chief executive officer of The CenterTX. “We are very excited to integrate VIPER into our clinical trial program, as it will not only help assist in growing our research capabilities, but it will also provide the practice with quality metrics, improved operational support and present our care teams a more effective method by which to match patients to trials.”
It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, patient participation in these trials is often as low as three percent. Limited site capacity and resources play a role in the challenge to recruit and enroll, as well as low patient engagement. All of these challenges have been magnified by the current global pandemic. VIPER automates the clinical trial screening process and seamlessly matches patients — at the time of diagnosis — to appropriate trials through the ingestion and analysis of customized genomic data, electronic medical records and pathology data.
“The CenterTX is a standout oncology practice that is nationally recognized as a leader in research, value-based care and patient satisfaction. The CenterTX leadership has always sought out and adopted the newest, most innovative tools designed to improve patient care and we are thrilled that VIPER will be included in their already-exceptional offering,” said Greg Andreola, chief revenue officer at Deep Lens. “This collaboration will provide The CenterTX the ability to accelerate enrollment in clinical trials and will help reinforce its leadership in the oncology community by offering an increased number of precision medicine trials.”
Deep Lens’ VIPER will be integrating directly to The CenterTX’s EMR (VieCure), molecular data feeds (Foundation Medicine, Caris Life Sciences, Tempus, Guardant Health) and pathology feeds to automatically identify qualified patients for clinical trials. Like The CenterTX, any practice that utilizes VieCure can easily integrate VIPER and all other Deep Lens screening services free of charge.
About The Center for Cancer and Blood Disorders
The Center for Cancer and Blood Disorders is an all-encompassing team of cancer specialists that will fight for its patients- every step of the way. Its team of physicians put patients at the center of a coordinated health plan, with everyone from the oncologists, nurses and patient navigators to nutritionists, pharmacists, counselors, and support groups working together to provide access to the most advanced technologies, groundbreaking treatments, and compassionate cancer care. With 25 cancer specialists practicing in 10 locations across Tarrant and surrounding western counties, patients can access the research knowledge and clinical expertise of one of the nation’s most highly respected cancer centers. Learn more at: www.thecentertx.com.
About Deep Lens
Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. VIPER, Deep Lens’ integrated cloud platform, provides care teams with visibility and workflows that combine lab, EMR, and genomic data to match cancer patients to clinical trials and precision therapies at the time of diagnosis, accelerating recruitment and compressing study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the best therapies. For more information, visit www.deeplens.ai.